Zobrazeno 1 - 10
of 142
pro vyhledávání: '"M. Magrey"'
Publikováno v:
Rheumatology International.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4f37c2a9f070ff0ca58074c97daba9ef
https://doi.org/10.1007/s00296-023-05322-5
https://doi.org/10.1007/s00296-023-05322-5
Autor:
M Magrey, A Deodhar, PJ Mease, V Navarro-Compán, S Ramiro, M Rudwaleit, C de la Loge, C Fleurinck, V Taieb, MF Mørup, M Oortgiesen, J Kay
Publikováno v:
Value in Health. 25:S427-S428
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5929a0db629b4729f4bc0b11b18bd526
https://doi.org/10.1016/j.jval.2022.09.2129
https://doi.org/10.1016/j.jval.2022.09.2129
Autor:
M. Breban, A. Deodhar, D. Van Der Heijde, L.S. Gensler, H. Xu, K. Gaffney, H. Dobashi, W. Maksymowych, M. Rudwaleit, M. Magrey, D. Elewaut, M. Oortgiesen, C. Fleurinck, N. De Peyrecave, A.M. Ellis, T. Vaux, J. Sheperd-Smith, X. Baraliakos
Publikováno v:
Revue du Rhumatisme. 89:A138-A139
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::40b33cac5f5d74713cbf76a9befd6765
https://doi.org/10.1016/j.rhum.2022.10.203
https://doi.org/10.1016/j.rhum.2022.10.203
Autor:
M. Dougados, P.J. Mease, A. Deodhar, M. Dubreuil, M. Magrey, H. Marzo-Ortega, M. Rudwaleit, C. De La Loge, A.M. Ellis, C. Fleurinck, M. Oortgiesen, V. Taieb, L.S. Gensler
Publikováno v:
Revue du Rhumatisme. 89:A239-A240
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bbf706dca24bbec18640c4e01fc8f1d6
https://doi.org/10.1016/j.rhum.2022.10.376
https://doi.org/10.1016/j.rhum.2022.10.376
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
A. Deodhar, D. Van der Heijde, L. S. Gensler, H. Xu, K. Gaffney, H. Dobashi, W. P. Maksymowych, M. Rudwaleit, M. Magrey, D. Elewaut, M. Oortgiesen, C. Fleurinck, A. Ellis, T. Vaux, J. Smith, X. Baraliakos
Publikováno v:
Annals of the Rheumatic Diseases. 81:772-773
BackgroundBimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits IL-17F in addition to IL-17A. BKZ has shown rapid and sustained efficacy and was well tolerated up to 156 weeks (wks) in a phase 2b study in patients (pts) with activ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ce61cbe31dccad4b60c3e3bdaa81490e
https://doi.org/10.1136/annrheumdis-2022-eular.2416
https://doi.org/10.1136/annrheumdis-2022-eular.2416
Autor:
A. Deodhar, S. Akar, J. Curtis, B. Zorkany, M. Magrey, C. Wang, J. Wu, S. B. Makgoeng, I. Vranic, S. Menon, D. Fleishaker, A. Diehl, L. Fallon, A. Yndestad, R. B. M. Landewé
Publikováno v:
Annals of the Rheumatic Diseases. 81:394-395
BackgroundTofacitinib is an oral JAK inhibitor for the treatment of adults with ankylosing spondylitis (AS).ObjectivesTo describe the tofacitinib safety profile from an integrated analysis of randomised controlled trials (RCTs) in patients (pts) with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e12e046b04e96cf385c78fed230ed483
https://doi.org/10.1136/annrheumdis-2022-eular.2076
https://doi.org/10.1136/annrheumdis-2022-eular.2076
Autor:
M. Magrey, M. Jain, R. Ranza, J. Stigler, E. Mcdearmon-Blondell, C. Yue, B. Padilla, C. Kaufmann, D. Mcgonagle
Publikováno v:
Annals of the Rheumatic Diseases. 81:849-850
BackgroundControlling or improving musculoskeletal disease activity of psoriatic arthritis (PsA) (eg, enthesitis and associated pain) is a treatment priority for patients, rheumatologists, and dermatologists.1 Enthesitis is the cardinal lesion in PsA
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1bf1267854ce4e08b7f18b4ebb8b3863
https://doi.org/10.1136/annrheumdis-2022-eular.3161
https://doi.org/10.1136/annrheumdis-2022-eular.3161
Autor:
A. Deodhar, A. Kivitz, M. Magrey, J. A. Walsh, P. J. Mease, M. Greenwald, R. Calheiros, F. Kianifard, C. Elam, K. Nagar, A. Winseck, L. S. Gensler
Publikováno v:
Annals of the Rheumatic Diseases. 81:16-17
BackgroundAnkylosing spondylitis (AS) is a chronic, systemic inflammatory condition characterized by inflammatory back pain and is associated with extra-musculoskeletal manifestations and systemic comorbidities. Secukinumab (SEC) doses of 150 mg and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::97478dead6bf115a7782637f286c5695
https://doi.org/10.1136/annrheumdis-2022-eular.209
https://doi.org/10.1136/annrheumdis-2022-eular.209
Autor:
A. Deodhar, D. Poddubnyy, R. Blanco, S. Hall, M. Magrey, E. Quebe-Fehling, R. Calheiros, P. Pertel, H. Marzo-Ortega
Publikováno v:
Annals of the Rheumatic Diseases. 81:1505-1506
BackgroundPatients (pts) with axial spondyloarthritis (axSpA) often experience delayed diagnosis, which can lead to treatment delay1. However, earlier diagnosis and treatment of axSpA pts can lead to a greater clinical response2. Secukinumab (SEC) 15
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c73d76548c1e6208fed63e7de1572409
https://doi.org/10.1136/annrheumdis-2022-eular.1732
https://doi.org/10.1136/annrheumdis-2022-eular.1732